🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Supernus, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
29.27
+0.23 (0.77%)
Nov 18, 2026, 1:00 PM EST - Market open

Company Description

Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.

It develops medicines to treat substance use disorders. The company’s core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film.

It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD).

In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Supernus, Inc. was formerly known as Indivior Pharmaceuticals, Inc. and changed its name Supernus, Inc. in November 2026.

Supernus, Inc. was incorporated in 2014 and is headquartered in Rockville, Maryland.

Supernus, Inc.
Supernus logo
CountryUnited States
Founded2005
IPO DateMay 1, 2012
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees838
CEOJack Khattar

Contact Details

Address:
9715 Key West Avenue
Rockville, Maryland 20850
United States
Phone301 838 2500
Websitesupernus.com

Stock Details

Ticker SymbolSUPN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code1625297
CUSIP Number45579U109
ISIN NumberUS45579U1097
Employer ID41-2520873
SIC Code2834

Key Executives

NamePosition
Jack A. Khattar M.B.A.President, Chief Executive Officer and Director
Dr. Christian HeidbrederChief Scientific Officer
Timothy C. DecSenior Vice President and Chief Financial Officer
Jason ThompsonVice President of Investor Relations
Kevin L. EspinozaChief Integrity and Compliance Officer
Angela Colon-Mahoney M.S.Chief Human Resources Officer
Vanessa ProcterExecutive Vice President of Corporate Affairs
Dr. Ann Wheeler Pharm.D.Chief Medical Officer
Ken MoriciSenior Vice President of Manufacturing and Supply
Alice Grace GivensCompany Secretary

Latest SEC Filings

DateTypeTitle
Nov 3, 20268-KCurrent Report
Nov 2, 20268-KCurrent Report
Oct 29, 202610-QQuarterly Report
Oct 29, 2026425Filing
Oct 29, 20268-KCurrent Report
Oct 15, 20268-KCurrent Report
Oct 6, 2026425Filing
Oct 6, 20268-KCurrent Report
Sep 30, 2026SCHEDULE 13GFiling
Sep 17, 2026425Filing
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides